Observational studyPloS one2025
Peripheral line for vasopressor administration: Prospective multicenter observational cohort study for survival and safety.
Observational study in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incidence of Adverse Events in Peripheral Intravenous Vasopressor Use: A Systematic Review and Meta-Analysis.JAMA network open · 2026Pooled it
- Navigating the veins: A comprehensive review of vasoactive agent infusionWorld journal of critical care medicine · 2026Review
- Safety of Administration of Vasopressors Through Peripheral Compared to Central Venous Catheters in a Rural Kenyan Hospital: Protocol for a Prospective Observational Cohort Study.JMIR research protocols · 2026Observational
- Utility of a Peripheral Intravenous Catheter for Administration of Vasopressors: A Narrative Review.Cureus · 2026Review
- Management of arterial hypotension in critically Ill children: a narrative review and practical approach.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe placement of a central venous catheter (CVC) is associated with a high risk of central line-related bacteremia and mechanical complications. In a resource-constrained environment, the use of CVC is limited as a result of the complexity of the procedure and the need for a trained expert to place it. There is scant evidence on the feasibility, outcome, and safety of administering vasopressors using a peripheral venous catheter (PVC). Hence, our study, which is the first of its kind, evaluated the survival outcome, predictors, and safety of vasoactive drug administration via peripheral intravenous access in patients with circulatory shock.
methodsA prospective cohort study was conducted in the Emergency Department and ICU setting of selected public and private hospitals in Addis Ababa on selected 250 circulatory shock patients over 6 months for whom vasopressor was administered peripherally. Data was collected daily using ODK by study site coordinators and trained data collectors. Statistical analysis was done using STATA 14.1 using descriptive analysis, Kaplan Meir survival analysis, and cox regression analysis.
resultsThe median (IQR) age of the participants was 48.5 (35, 62). From circulatory shock causes, septic and cardiogenic shock accounted for 69.6% and 22.0% respectively. There were 3 extravasation injuries from the 250 patients that occurred exclusively on patients that took vasopressor for more than 4 days yielding an event rate of 1.2% and 0.004/patient day. Mortality in circulatory shock patients is high with a 57.6% mortality rate in general and 67.8% in septic shock patients. A Cox regression analysis identified decreased baseline systolic blood pressure [AHR = 0.98; 95%CI: 0.95, 0.99], decreased urine output [AHR = 0.96; 95%CI: 0.93, 0.99], septic shock compared to cardiogenic shock [AHR = 0.48; 95%CI: 0.24, 0.94], and use vasopressor other than norepinephrine [AHR = 0.6; 95%CI: 0.39, 0.92] as independent predictors of death of circulatory shock patients with peripherally administered vasopressors.
conclusionOur study found that peripheral venous catheter use for vasopressor administration in circulatory shock was associated with a low extravasation rate (1.2%), with all events occurring after more than five days, indicating it might be a safe alternative to CVC for short-term use in resource-limited settings. Findings support cautious prolonged use and consideration of central access when therapy exceeds a few days. This calls for randomized controlled trials to compare the safety and efficacy of vasopressor administration by PVC versus CVC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.